Annexin Pharmaceuticals AB operates as a biotechnology company. It develops treatment of various cardiovascular diseases. The firm establishes and optimizes a cell line for large-scale production of Annexin A5. The company was founded by Anna Frostegård in 2014 and is headquartered in Stockholm, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company